Grant: Collaborative Health Research Projects (NSERC partnered)

Antibiotic resistance has reached crisis proportions. It is the product of natural selection and is inexorable, yet the crippling effect of drug resistant infectious diseases can be mitigated by continuous development of novel antibacterial medicines. To this end, the Brennan, Brown and Wright research groups have had much success with innovative and collaborative strategies to uncover and characterize novel antibiotic chemicals, and are now ideally positioned to translate this research toward industrial drug development. The proposed research is a synergistic application of the unique strengths born from each of these internationally competitive research programs and will be leveraged by the experience of a seasoned industrial drug discovery partner, namely AstraZeneca. Together, this team will engage in a concerted effort to bring novel antibiotic derived from natural sources from the discovery phase through to pre-clinical evaluation.